AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28914087
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (12 sessions)
Trial: 16686645
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) 600 mg/day
Trial: 11741555
Drug: High-dose dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dobutamine stress echocardiography (up to 40 micro/kg/min)
Trial: 11741555
Drug: High-dose dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dobutamine stress echocardiography
Trial: 7587599
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) treatment, 3 x 10(6) U/day for 14 weeks
Trial: 105697
Drug: Stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stannous fluoride toothpaste used twice yearly for three years in supervised brush-ins
Trial: 31013820
Drug: Sodium Citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Citrate (CIT) 600 mg·kg‐1
Trial: 27660163
Drug: Bimonthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimonthly intravitreal injections of aflibercept (IVA)
Trial: 28402983
Drug: Pro re
RxNorm normalized name: Blistex Pro Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro re nata (PRN) treatment
Trial: 26690036
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration Training (WBVT) for 6 weeks, 3 sessions per week, intensity varied from 7.2 g to 32.6 g
Trial: 22083471
Drug: LAMB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAMB (3 mg/kg once a day)
Trial: 22083471
Drug: CAS (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS (50 mg QD; day 1, 70 mg)
Trial: 22083471
Drug: CAS-LAMB (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS-LAMB (combination therapy)
Trial: 19922894
Drug: DPSGC 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 25 mg under fasted condition
Trial: 19922894
Drug: DPSGC 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 25 mg under fed condition
Trial: 19922894
Drug: DPSGC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 50 mg under fasted condition
Trial: 19922894
Drug: DPSGC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 50 mg under fed condition
Trial: 1257173
Drug: Inert pill
RxNorm normalized name: inert ingredients Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert pill (placebo)
Trial: 1257173
Drug: Early drug
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early drug withdrawal
Trial: 23594787
Drug: EOC (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOC (epirubicin 50 mg/m², oxaliplatin 130 mg/m², capecitabine 1250 mg/m²)
Trial: 23594787
Drug: mEOC+P (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mEOC+P (epirubicin 50 mg/m², oxaliplatin 100 mg/m², capecitabine 1000 mg/m², panitumumab 9 mg/kg)
Trial: 12505859
Drug: 12-month maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12-month maintenance intervention with weekly telephone contacts and monthly supervised reinforcement sessions (n = 87)
Trial: 9049568
Drug: Zinc (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (25 mg zinc as sulphate)
Trial: 9049568
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg zinc as sulphate)
Trial: 9049568
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch containing capsules)
Trial: 22686358
Drug: Web-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive-behavioral therapy (CBT) for 12 weeks
Trial: 19860985
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Ca as calcium carbonate
Trial: 17915969
Drug: Topiramate (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (target daily dose, 200 mg) plus cognitive-behavior therapy (CBT)
Trial: 17915969
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cognitive-behavior therapy (CBT)
Trial: 15697072
Drug: Flutamide 250
RxNorm normalized name: flutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 250 mg daily
Trial: 12153602
Drug: CPA 2
RxNorm normalized name: Cyproterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA 2 mg with 35 micro g ethinylestradiol
Trial: 12153602
Drug: CPA 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA 50 mg with 25 micro g ethinylestradiol
Trial: 11446841
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg daily
Trial: 10434235
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg (oral single dose)
Trial: 7607582
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HELP treatment)
Trial: 30151821
Drug: Dalteparin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter)
Trial: 26254585
Drug: Glycopyrrolate 10
RxNorm normalized name: glycopyrrolate 100% compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 10 μg/kg
Trial: 26254585
Drug: Atropine 15
RxNorm normalized name: morphine sulfate/atropine 15/0.4 INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 15 μg/kg
Trial: 23157466
Drug: Dalfampridine-ER 10
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine-ER 10 mg twice daily
Trial: 21545485
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg with fluconazole 200 mg
Trial: 21545485
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg alone
Trial: 11006189
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg lignocaine
Trial: 12645862
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg lignocaine
Trial: 28890326
Drug: TauroLock™‐Hep500 used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TauroLock™‐Hep500 used twice per week and TauroLock™‐U25,000 once a week
Trial: 24297945
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg intravenously, weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Trial: 24297945
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (9 MIU subcutaneously thrice weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Trial: 12543884
Drug: Balloon angioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon angioplasty (plus medication if necessary)
Trial: 11696071
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg sustained-release melatonin 0.5 h before daytime sleep episodes
Trial: 16298773
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg sustained-release melatonin
Trial: 9715537
Drug: Sequential follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential follow-up study
Trial: 3107483
Drug: Non-steroidal antirheumatic
RxNorm normalized name: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal antirheumatic drug therapy
Trial: 31760817
Drug: Two letters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two letters plus educational material and a counseling call (CC)
Trial: 30224584
Drug: Brief Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Cognitive Behavioral Therapy for Insomnia (CBT-I)
Trial: 28127948
Drug: Reformulated DTC
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated DTC capsule (Duodart®) 0.5 mg dutasteride and 0.4 mg tamsulosin
Trial: 28127948
Drug: Commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial formulation of dutasteride and tamsulosin
Trial: 23739024
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for alcohol use disorders
Trial: 19846269
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg i.v.) or Prednisone (40 mg by mouth × 2 days)
Trial: 16614786
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training combined with child therapy (CT)
Trial: 15378678
Drug: mecamylamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mecamylamine (15 mg; oral)
Trial: 15378678
Drug: scopolamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine (0.4 mg, s.c.)
Trial: 15378678
Drug: mecamylamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mecamylamine (15 mg) + scopolamine (0.4 mg)
Trial: 11520711
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg twice a day
Trial: 11520711
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg twice a day (in Australasian population)
Trial: 22585212
Drug: Miltefosine dosing
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine dosing algorithm based on allometric scaling
Trial: 22585212
Drug: Allometric dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allometric dosing algorithm for miltefosine
Trial: 22585212
Drug: New allometric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New allometric dosing algorithm for miltefosine
Trial: 15942317
Drug: Regranex Gel
RxNorm normalized name: becaplermin Topical Gel [Regranex]
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regranex Gel
Trial: 12843202
Drug: Ghrelin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (1 micro g/Kg iv)
Trial: 12843202
Drug: GHRH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (1 micro g/Kg iv)
Trial: 12843202
Drug: GHRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH plus Ghrelin (1 micro g/Kg iv)
Trial: 10472341
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog triptorelin (3.75 mg i.m. monthly)
Trial: 10472341
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of triptorelin and aromatase inhibitor formestane (4‐OHA, 500 mg i.m. fortnightly)
Trial: 8933496
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (5 g creatine monohydrate 4 times per day for 5 days)
Trial: 8933496
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosage of a lactose placebo)
Trial: 1655227
Drug: Cisplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (120 mg/m2) and Doxorubicin (70 mg/m2) every 3 weeks for four cycles
Trial: 1655227
Drug: Cyclophosphamide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (1000 mg/m2 every 21 days for six cycles)
Trial: 1655227
Drug: Whole-abdominal radiation
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-abdominal radiation therapy
Trial: 1655227
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (refusal of SLL)
Trial: 26624976
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate MDPI 800 μg (total dose 800 μg)
Trial: 26624976
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate MDPI 400 μg (total dose 400 μg)
Trial: 26624976
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate Diskus 400 μg (total dose 400 μg)
Trial: 26624976
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate MDPI 800 μg
Trial: 26624976
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate MDPI 400 μg
Trial: 26624976
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate Diskus 400 μg
Trial: 22548646
Drug: Canagliflozin 50
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 50 mg, 100 mg, 200 mg, 300 mg daily, or 300 mg twice daily
Trial: 20467641
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g amoxicillin
Trial: 1819435
Drug: High-dose Edmonston-Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Edmonston-Zagreb or AIK-C at 4-5 months
Trial: 1819435
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose Schwarz at 8-10 months
Trial: 7274609
Drug: MgCl2 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgCl2 (60 mmole daily)
Trial: 7274609
Drug: Mg(OH)2 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg(OH)2 (60 mmole daily)
Trial: 30520566
Drug: Pegbelfermin 20
RxNorm normalized name: Pegbelfermin
DrugBank: Pegbelfermin (DB15365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbelfermin 20 mg daily
Trial: 30520566
Drug: Pegbelfermin (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbelfermin (1, 5, or 20 mg daily or 20 mg weekly)
Trial: 30520566
Drug: Pegbelfermin 20
RxNorm normalized name: Pegbelfermin
DrugBank: Pegbelfermin (DB15365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbelfermin 20 mg daily and weekly
Trial: 15053242
Drug: Metyrapone test
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metyrapone test (30 mg/kg orally at 23:00 h)
Trial: 15842577
Drug: Valdecoxib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (10 and 20 mg once daily)
Trial: 15842577
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg three times daily)
Trial: 10561336
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg on alternate days
Trial: 10561336
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg/d
Trial: 6362245
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine (N)
Trial: 6362245
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbiddinitrate (I)
Trial: 6362245
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 mg isosorbiddinitrate and 20 mg nifedipine (I + N)
Trial: 31727687
Drug: Every 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 0.1 mL/min/1.73 m2 predicted annual fall in eGFR
Trial: 30725411
Drug: Methionine-restricted total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine-restricted total parenteral nutrition (MR TPN) with chemotherapy-containing amino acid solution (AO-90)
Trial: 30725411
Drug: 1-day methionine-restricted
RxNorm normalized name: methionine 1.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day methionine-restricted diet combined with cystemustine (60 mg/m2 every 2 weeks)
Trial: 12622925
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 1.5 mg/d plus micronized progesterone (MP) 100 mg/d
Trial: 12622925
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 1.5 mg/d plus medroxyprogesterone acetate (MPA) 2 mg/d
Trial: 12622925
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 0.75 mg/d plus micronized progesterone (MP) 100 mg/d
Trial: 12622925
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 0.75 mg/d plus medroxyprogesterone acetate (MPA) 2 mg/d
Trial: 7851681
Drug: Chronic euglycaemic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic euglycaemic hyperinsulinaemia (+72 pmol/l) for 72-96 hours
Trial: 7851681
Drug: Chronic hyperglycaemic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic hyperglycaemic hyperinsulinaemia (+78 pmol/l) for 72 hours
Trial: 30120832
Drug: Serratus anterior
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus anterior plane block with 30 ml ropivacaine 0.375%
Trial: 28477992
Drug: iNPWT (intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNPWT (intervention negative pressure wound therapy)
Trial: 8346826
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anesthesia (CSA) with 0.5% bupivacaine, initial dose 1 mL, reinjection 1 mL
Trial: 8346826
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural anesthesia (CEA) with 0.5% bupivacaine, initial dose 10 mL, reinjection 5 mL
Trial: 8346826
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anesthesia (SSA) with 0.5% bupivacaine, initial dose 3 mL
Trial: 20701016
Drug: CKD screening
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD screening tests (e.g., glomerular filtration rate)
Trial: 19146124
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B Indicator
Trial: 15990003
Drug: LCAF+CT (Late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCAF+CT (Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy)
Trial: 19753739
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day itraconazole for 3 days
Trial: 19753739
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day itraconazole for 1 day
Trial: 19753739
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day itraconazole for 5 days
Trial: 2028586
Drug: Dexamethasone, 4
RxNorm normalized name: Dexamethasone, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 4 mg
Trial: 2028586
Drug: Acetazolamide, 250
RxNorm normalized name: AcetaZOLAMIDE, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide, 250 mg
Trial: 31280790
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy (CBGT) + 4 resilience and coping strategy sessions (total 16 sessions)
Trial: 20335572
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus nadroparin (2850 IU)
Trial: 20335572
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (80 mg)
Trial: 7774735
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) gel (2 mg for primigravidae, 1 mg for parous)